<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27963" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pustular Psoriasis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Muneeb</given-names>
          </name>
          <aff>Penn State Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Aboud</surname>
            <given-names>Daifallah M.</given-names>
          </name>
          <aff>TAIF University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Crane</surname>
            <given-names>Jonathan S.</given-names>
          </name>
          <aff>Sampson Regional Med Ctr / Campbell Univ</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>VA Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muneeb Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daifallah Al Aboud declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Crane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Kumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27963.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pustular psoriasis is a rare, immune-mediated systemic skin disorder characterized by yellowish pustules on an erythematous base with a variety of clinical presentations and distribution patterns. Pustular psoriasis is considered a variant of psoriasis vulgaris. The pustules can be widespread or localized and are characterized by a sterile, predominantly neutrophilic infiltrate. This activity reviews the pathophysiology of pustular psoriasis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Recall the etiology of pustular psoriasis.</p></list-item><list-item><p>Describe the presentation of pustular psoriasis.</p></list-item><list-item><p>Summarize the treatment options for pustular psoriasis.</p></list-item><list-item><p>Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by pustular psoriasis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27963&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27963">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27963.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pustular psoriasis is a rare, immune-mediated systemic skin disorder characterized by yellowish pustules on an erythematous base with a variety of clinical presentations and distribution patterns.<xref ref-type="bibr" rid="article-27963.r1">[1]</xref>&#x000a0;Pustular psoriasis is considered a&#x000a0;variant&#x000a0;of psoriasis vulgaris.&#x000a0;The pustules can be widespread or localized and are characterized by a sterile predominantly neutrophilic infiltrate.&#x000a0;Unlike chronic plaque psoriasis (the most common variant of psoriasis vulgaris), lesions of pustular psoriasis are often tender&#x000a0;to palpation.<xref ref-type="bibr" rid="article-27963.r2">[2]</xref>&#x000a0;Pustular psoriasis can be further subdivided based on the clinical presentation and the location of pustules.&#x000a0;</p>
        <p>Subtypes of pustular psoriasis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Generalized:
<list list-type="bullet"><list-item><p>von Zumbusch subtype: Diffuse generalized pustular eruption with associated systemic symptoms (fevers, arthralgias, etc.)</p></list-item><list-item><p>Annular subtype: Annular lesions with pustules along the advancing edge.</p></list-item><list-item><p>Exanthematic subtype: Acute pustular eruption without systemic symptoms that resolves after a few days.&#x000a0;</p></list-item><list-item><p>Impetigo herpetiformis: Pustular psoriasis occurring during pregnancy.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Localized:
<list list-type="bullet"><list-item><p>Acrodermatitis continua of Hallopeau:&#x000a0;Pustules affecting the fingers, toes, and nail beds.&#x000a0;</p></list-item><list-item><p>Palmoplantar psoriasis: Pustules affecting the palms and soles</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27963.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Pustular psoriasis occurs in genetically susceptible individuals and can be triggered by certain risk factors&#x000a0;leading to psoriasiform changes and marked neutrophil accumulation in the epidermis.<xref ref-type="bibr" rid="article-27963.r3">[3]</xref>&#x000a0;Patients with pustular psoriasis have an increased frequency of the HLA-B27&#x000a0;allele compared to the general population. Most cases of pustular psoriasis are idiopathic, however, risk factors that may have a role in the etiology of pustular psoriasis include <xref ref-type="bibr" rid="article-27963.r4">[4]</xref><xref ref-type="bibr" rid="article-27963.r5">[5]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sudden&#x000a0;withdrawal of systemic steroids</p>
          </list-item>
          <list-item>
            <p>Skin infections&#x000a0;(<italic toggle="yes">Staphylococcus aureus)</italic></p>
          </list-item>
          <list-item>
            <p>Electrolytes&#x000a0;imbalance; hypocalcemia (i.e., von Zumbusch subtype)</p>
          </list-item>
          <list-item>
            <p>Medications&#x000a0;(lithium, iodine, penicillin, interferon-alpha, etc.)</p>
          </list-item>
          <list-item>
            <p>Pregnancy (i.e., impetigo herpetiformis)</p>
          </list-item>
          <list-item>
            <p>Phototherapy</p>
          </list-item>
          <list-item>
            <p>Vaccinations (BCG and H1N1)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27963.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Pustular psoriasis is a rare disease. It&#x000a0;affects both children and adults in a bimodal age distribution.&#x000a0;In the adult age group, the disorder appears between ages 40 to 50, whereas in the pediatric age group, it tends to present in infancy. Asians tend to be more affected than Caucasians.<xref ref-type="bibr" rid="article-27963.r6">[6]</xref>&#x000a0;Women and men are affected equally. The pustular variants of psoriasis represent approximately 1% of all clinical cases of psoriasis vulgaris.<xref ref-type="bibr" rid="article-27963.r5">[5]</xref></p>
      </sec>
      <sec id="article-27963.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathogenesis of pustular psoriasis has not been fully elucidated. However, based on the expression of certain cytokines and responses to specific medications, several mechanisms have been proposed. A combination of genetic susceptibility and exposure to certain inciting factors (e.g., withdrawal of systemic corticosteroids) lead to an upregulation of specific cytokines and accumulation of neutrophils in the epidermis.<xref ref-type="bibr" rid="article-27963.r5">[5]</xref>&#x000a0;Additionally, dermal dendritic cells&#x000a0;release elastase, which may play a role in the formation of pustules.<xref ref-type="bibr" rid="article-27963.r7">[7]</xref>&#x000a0;Both pustular psoriasis and chronic plaque psoriasis exhibit overexpression of IL-1, IL-17, IL-23, IL-36, TNF-alpha, and IFN-gamma. However, the expression of IL-1 and IL-36 are more prominent in pustular psoriasis. Studies have also identified an IL-36 receptor antagonist deficiency in patients with pustular psoriasis and patients with pustular psoriasis have&#x000a0;also been successfully treated with a novel monoclonal antibody against the IL-36 receptor.<xref ref-type="bibr" rid="article-27963.r8">[8]</xref> Therefore, IL-36&#x000a0;likely plays a&#x000a0;critical role in the pathogenesis of pustular psoriasis.&#x000a0;</p>
      </sec>
      <sec id="article-27963.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Many of the histopathological features of pustular psoriasis mimic that of psoriasis vulgaris, including retention of the nuclei in the stratum corneum (parakeratosis), a thick stratum spinosum (hyperkeratosis), elongation of the rete ridges,&#x000a0;reduced stratum granulosum, and thinning of the suprapapillary epidermis.<xref ref-type="bibr" rid="article-27963.r5">[5]</xref>&#x000a0;In addition to the classic histologic features of psoriasis vulgaris, there is also a prominent&#x000a0;neutrophilic infiltrate in the papillary dermis and epidermis, causing basal keratinocytes to herniate into the papillary dermis disrupting desmosomal junctions of keratinocytes&#x000a0;(spongiosis), and leading to the development of superficial&#x000a0;micro-abscesses<italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-27963.r9">[9]</xref>&#x000a0;Neutrophilic infiltration of the epidermis is more prominent in pustular psoriasis than other variants of psoriasis vulgaris.&#x000a0;</p>
      </sec>
      <sec id="article-27963.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Pustular psoriasis appears as numerous discrete or confluent superficial, yellowish pustules on a background of erythema. Pustular psoriasis can be diffuse or localized. A&#x000a0;full body skin examination should be performed, including&#x000a0;careful evaluation of the mucous membranes and the nails for other signs of psoriasis and to exclude other causes of pustulosis.&#x000a0;</p>
        <p>Pustular psoriasis starts as red papules or plaques that quickly evolve into yellowish, superficial pustules on a background of erythema. The generalized von Zumbusch subtype usually presents with systemic symptoms like fever, joint pain, headaches, and leukocytosis. In contrast, the exanthematic subtype presents as an acute pustular eruption without systemic symptoms. The annular subtype is seen more frequently in children as annular lesions with pustules along the advancing edge.<xref ref-type="bibr" rid="article-27963.r10">[10]</xref>&#x000a0;Acrodermatitis continua of Hallopeau affects the finger, toes, and nailbeds. Palmoplantar psoriasis, which can be seen as part of SAPHO syndrome, affects the palms and soles.</p>
      </sec>
      <sec id="article-27963.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients with suspected pustular psoriasis require careful evaluation, as the von Zumbusch subtype can be life-threatening. Laboratory investigations should include a complete blood count (CBC) to evaluate for leukocytosis, an electrolyte panel to assess for hypocalcemia, and a liver panel to assess for&#x000a0;transaminitis. A pregnancy test should be ordered in all women of childbearing age. A punch biopsy&#x000a0;can be performed in equivocal cases. Cultures of weeping lesions may be useful to exclude primary or secondary infections.&#x000a0;</p>
      </sec>
      <sec id="article-27963.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The first step in managing cases of pustular psoriasis is&#x000a0;identifying disease triggers, such as an underlying infection.&#x000a0;Generalized pustular psoriasis (e.g., von Zumbusch subtype)&#x000a0;may require admission to the hospital. Systemic symptoms including fever and joint pain will require treatment with antipyretics and anti-inflammatory medications. Disease-specific medications including systemic retinoids (acitretin, isotretinoin), methotrexate, cyclosporine, and infliximab are considered first-line in adult patients. In pediatric patients,&#x000a0;acitretin, cyclosporine, methotrexate, and etanercept are preferred.<xref ref-type="bibr" rid="article-27963.r11">[11]</xref></p>
        <p>Second line options include systemic treatments in diffuse disease (e.g., etanercept and adalimumab) or topical treatments in localized disease (e.g., corticosteroids, calcipotriene, and&#x000a0;tacrolimus). All of these options can be used as monotherapy or in combination with first-line options.<xref ref-type="bibr" rid="article-27963.r12">[12]</xref>&#x000a0;Phototherapy is another treatment option.<xref ref-type="bibr" rid="article-27963.r13">[13]</xref>&#x000a0;Early delivery is recommended in pregnant patients with impetigo herpetiformis.</p>
        <p>Recent reports indicate the successful use of IL-1 receptor antagonists (e.g., anakinra) and&#x000a0;IL-36 receptor antagonists in treating pustular psoriasis.<xref ref-type="bibr" rid="article-27963.r8">[8]</xref>&#x000a0;Tocilizumab, a monoclonal antibody against the IL-6 receptor, has also shown efficacy in some recalcitrant cases of pustular psoriasis.<xref ref-type="bibr" rid="article-27963.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27963.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute generalized exanthematous pustulosis</p>
          </list-item>
          <list-item>
            <p>Drug eruption reaction</p>
          </list-item>
          <list-item>
            <p>Pemphigus vulgaris</p>
          </list-item>
          <list-item>
            <p>Pemphigus foliaceous</p>
          </list-item>
          <list-item>
            <p>Impetigo</p>
          </list-item>
          <list-item>
            <p>Dermatitis Herpetiformis</p>
          </list-item>
          <list-item>
            <p>Infected eczema</p>
          </list-item>
          <list-item>
            <p>Erythroderma</p>
          </list-item>
          <list-item>
            <p>Acute cutaneous lupus</p>
          </list-item>
          <list-item>
            <p>Dyshidrotic eczema</p>
          </list-item>
          <list-item>
            <p>Disseminated herpes simplex virus</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27963.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Pustular psoriasis is a chronic disease marked by recurrent episodes or flares. Treatment is aimed to shorten the duration of relapse, prevent complications, and extend disease-free periods. Compared to other subtypes, the von Zumbusch subtype of pustular psoriasis&#x000a0;has a higher risk of mortality because of systemic involvement, especially with underlying comorbidities, such as cancer, renal failure, or liver failure. The localized subtypes of pustular psoriasis have a much lower risk of mortality.&#x000a0;</p>
      </sec>
      <sec id="article-27963.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Hypocalcemia</p>
          </list-item>
          <list-item>
            <p>Septicemia, especially in the generalized form</p>
          </list-item>
          <list-item>
            <p>Hyperthermia</p>
          </list-item>
          <list-item>
            <p>Liver damage</p>
          </list-item>
          <list-item>
            <p>Acute renal failure</p>
          </list-item>
          <list-item>
            <p>Malnutrition</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27963.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with psoriasis should be educated to avoid abrupt steroid withdrawal, which can trigger episodes of pustular psoriasis. Flaccid lesions should be treated with proper wound care to avoid complications and secondary infections.&#x000a0;</p>
      </sec>
      <sec id="article-27963.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management of pustular psoriasis requires an interprofessional team approach, including providers from primary care, dermatology, and infectious disease. A detailed history and complete physical examination are critical in diagnosing cases of pustular&#x000a0;psoriasis.&#x000a0;A&#x000a0;dermatologist can help in the initial diagnostic workup and to assess for complications. Depending on the surface area involved, admission to the hospital may be required (e.g., von Zumbusch subtype). In equivocal cases, a biopsy can be performed, as the differential diagnosis for pustulosis is rather vast. Treatment is targeted to prevent relapses and shorten the duration of flares.&#x000a0;</p>
      </sec>
      <sec id="article-27963.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27963&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27963">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/pustular-psoriasis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27963">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27963/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27963">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27963.s16">
        <fig id="article-27963.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Pustular Psoriasis.&#x000a0;Pustular psoriasis is a rare and extreme form of psoriasis characterized by the appearance of sterile pustules, which can take many patterns. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pustular__psoriasis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27963.s17">
        <fig id="article-27963.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Photo of pustular psoriasis showing multiple yellowish pustules with surrounding erythema. Contributed by Daifallah Al Aboud, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_3309" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27963.s18">
        <title>References</title>
        <ref id="article-27963.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsuchida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ansai</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oginezawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shinkuma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Generalized pustular psoriasis complicated with bullous pemphigoid.</article-title>
            <source>Int J Dermatol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>e66</fpage>
            <page-range>e66-e67</page-range>
            <pub-id pub-id-type="pmid">30516289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negrotto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Correale</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Palmar pustular psoriasis associated with teriflunomide treatment.</article-title>
            <source>Mult Scler Relat Disord</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>27</volume>
            <fpage>400</fpage>
            <page-range>400-402</page-range>
            <pub-id pub-id-type="pmid">30513502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epple</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paffhausen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Enk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sedlaczek</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Haenssle</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Chronic recurrent multifocal osteomyelitis with psoriatic skin manifestations in a 12-year-old female.</article-title>
            <source>Dermatol Pract Concept</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-298</page-range>
            <pub-id pub-id-type="pmid">30479859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madanagobalane</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Secukinumab in Generalized Pustular Psoriasis.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>464</fpage>
            <page-range>464-466</page-range>
            <pub-id pub-id-type="pmid">30505796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boehner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarini</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Eyerich</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review.</article-title>
            <source>Exp Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1067</fpage>
            <page-range>1067-1077</page-range>
            <pub-id pub-id-type="pmid">29852521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komatsuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chijiwa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Namiki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukaya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukuyasu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohnishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation.</article-title>
            <source>J Dermatol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-75</page-range>
            <pub-id pub-id-type="pmid">30474867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Investigation of Psoriasis Susceptibility Loci in Psoriatic Arthritis and a Generalized Pustular Psoriasis Cohort.</article-title>
            <source>J Investig Dermatol Symp Proc</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>S83</fpage>
            <page-range>S83-S85</page-range>
            <pub-id pub-id-type="pmid">30471759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachelez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Choon</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Marrakchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Shear</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Padula</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thoma</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Mar</month>
            <day>07</day>
            <volume>380</volume>
            <issue>10</issue>
            <fpage>981</fpage>
            <page-range>981-983</page-range>
            <pub-id pub-id-type="pmid">30855749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabeff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Safar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leducq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maruani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarrabay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Samimi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Successful therapy with secukinumab in a patient with generalized pustular psoriasis carrying homozygous IL36RN p.His32Arg mutation.</article-title>
            <source>Int J Dermatol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>e16</fpage>
            <page-range>e16-e17</page-range>
            <pub-id pub-id-type="pmid">30430544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Paulsboe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wetter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Salte</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kannan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gerstein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Namovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Todorovi&#x00107;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Seagal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Edelmayer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Viner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leys</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sadhukhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Honore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McGaraughty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis.</article-title>
            <source>Exp Dermatol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-120</page-range>
            <pub-id pub-id-type="pmid">30417427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meier-Schiesser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feldmeyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mellett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Yerly</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Navarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yawalkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Contassot</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis.</article-title>
            <source>J Invest Dermatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>139</volume>
            <issue>4</issue>
            <fpage>848</fpage>
            <page-range>848-858</page-range>
            <pub-id pub-id-type="pmid">30395846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>ZT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Genetic Polymorphism of IL36RN in Han Patients with Generalized Pustular Psoriasis Alone in Sichuan Region].</article-title>
            <source>Sichuan Da Xue Xue Bao Yi Xue Ban</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>582</fpage>
            <page-range>582-586</page-range>
            <pub-id pub-id-type="pmid">30378314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okubo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mabuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwatsuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Elmaraghy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Torisu-Itakura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morisaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakajo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>325</fpage>
            <page-range>325-332</page-range>
            <pub-id pub-id-type="pmid">30317671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27963.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cornelius</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial.</article-title>
            <source>Trials</source>
            <year>2018</year>
            <month>Oct</month>
            <day>03</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>534</fpage>
            <pub-id pub-id-type="pmid">30285894</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
